QCA Corporate Governance Code

RNS Number : 4328U

Shield Therapeutics PLC

25 November 2019

 

Shield Therapeutics plc

("Shield" or the "Group")

Shield Therapeutics plc adopts the Quoted Companies Alliance Corporate Governance Code

London, UK, 25 November 2019: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer^TM (ferric maltol), today announces that following Board approval the Company will be adopting the Quoted Companies Alliance Corporate Governance Code ("QCA Code"). This decision follows a review by the Board of Directors and is based on the size of the Company and its range of its organisational activities.

The Company does not intend to make any changes to its Board composition or to the constitution and membership of its Audit, Nomination and Remuneration Committees as a consequence of the adoption of the QCA Code.

Commenting, James Karis, Chairman of Shield Therapeutics plc, said: 

"High standards of corporate governance are fundamental to the continued growth and development of Shield. The Board and its committees play a key role in ensuring these high standards are supported through internal frameworks, policies and procedures for the long-term benefit of our shareholders."

Our website www.shieldtherapeutics.com will contain further details on how we comply with the QCA Code.

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Carl Sterritt, Chief Executive Officer	[phone]
Tim Watts, Chief Financial Officer
Nominated Advisor and Joint Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden	[phone]
Joint Broker finnCap Ltd      Geoff Nash/Matt Radley/Alice Lane	[phone]
Financial PR & IR Advisor
Walbrook PR	[phone] or [e-mail]
Paul McManus/Lianne Cawthorne	[phone] / [phone]

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs.  The Company's clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. The Group's lead product, Feraccru®/ Accrufer^TM has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland.  In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV and in the USA the product will be marketed as Accrufer^TM with Shield currently in the process of selecting a commercialisation partner. For more information please visit www.shieldtherapeutics.com

 

END

 

 

MSCPGGWAGUPBGQP